FTD-TPI plus bevacizumab found to increase survival in refractory advanced CRC

Treatment with trifluridine-tipiracil (FTD-TPI) plus bevacizumab yields longer overall survival than FTD-TPI alone among patients with refractory metastatic colorectal cancer, according to a study published in the May 4 issue of the New England Journal of Medicine.

Leave A Comment

Your email address will not be published. Required fields are marked *